Branched hydrazone linkers

Details Branched hydrazone linkers Branched hydrazone linkers

1996-12-19

1998-10-20

Ceperley, Mary E.

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

5303919, 548547, 548548, 564 34, 564 35, 564 37, 564151, C07D20740, C07C24328

Patent

active

058248056

ABSTRACT:
Branched hydrazone linkers for linking a targeting ligand such as an antibody to a therapeutically active drug. The point of branching is at a polyvalent atom and the number of drugs increases by a factor of two for each generation of branching. A preferred drug is doxorubicin.

REFERENCES:
patent: 4112217 (1978-09-01), Henry et al.
patent: 4263428 (1981-04-01), Apple et al.
patent: 4542225 (1985-09-01), Blattler et al.
patent: 4560512 (1985-12-01), Firestone
patent: 4618492 (1986-10-01), Blattler et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4675382 (1987-06-01), Murphy
patent: 4694064 (1987-09-01), Tomalia et al.
patent: 4699784 (1987-10-01), Shih et al.
patent: 4867973 (1989-09-01), Goers et al.
patent: 4950738 (1990-08-01), King et al.
patent: 5002883 (1991-03-01), Bieniarz et al.
patent: 5013547 (1991-05-01), Sweet et al.
patent: 5024834 (1991-06-01), Houston et al.
patent: 5055561 (1991-10-01), Packard et al.
patent: 5057301 (1991-10-01), Wilbur et al.
patent: 5057313 (1991-10-01), Shih et al.
patent: 5066490 (1991-11-01), Neville et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5094849 (1992-03-01), Cullinan et al.
patent: 5122368 (1992-06-01), Greenfield et al.
patent: 5137877 (1992-08-01), Kaneko et al.
patent: 5144012 (1992-09-01), Johnson et al.
patent: 5155210 (1992-10-01), Wrasidlo
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5198560 (1993-03-01), Kadow et al.
patent: 5208020 (1993-05-01), Chari et al.
R. Arnon, "Novel Application for Antibodies", Biotechnol. Appl. Proteins Enzymes, Pap. Conf., Z Bohak et al. (eds.), pp. 247-265 (Academic Press 1976) (Arnon 1).
R. Arnon, "Anti-Tumor Antibodies as Carriers For Anti-Cancer Drugs", Proc. Serono Symp. 16 (Tumor-Assoc. Antigens and Their Specific Immune Response), pp. 287-304 91979) (Arnon 11).
R. Arnon et al., "In Vitro and In Vivo Efficacy of Conjugates of Daunomycin with Anti-Tumor Antibodies", Immunological Rev., 62, pp. 5-27 (1982) (Arnon 111).
R. Arnon et al., "Antibodies and Dextran as Anti-Tumor Drug Carriers", NATO Adv. Study Inst. Ser., Ser A, 47 (Targeting Drugs), pp. 31-54 (1982) (Arnon IV).
R. Arnon et al., "Monoclonal Antibodies as Carriers for Immunotargeting of Drugs", Monoclonal Antibodies for Cancer Detection and Therapy, R. W. Baldwin et al. (eds.), pp. 365-383 (Academic Press 1985) (Arnon V).
R. Arnon et al., "Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy", Monoclonal Antibodies and Cancer Therapy, pp. 243-256, (Alan R. Liss, Inc. 1985) (Arnon VI).
N. R. Bachur, "Free Radical Damage", Anthracycline Antibiotics in Cancer Therapy, from Proc. Int. Symp. on Anthracycline Antibiotics in Cancer Therapy, F. M. Muggia et al. (eds.), pp. 97-102 (Martinus Nijhoff 1982).
R. W. Baldwin et al., "Monoclonal Antibodies toa Tumor Specific Antigen on Rat Mammary Carcinoma Sp4 and Their Use in Drug Delivery Systems", Hybridomas Cell. Immortality, Proc. Natl. Symp., B. H. Tom et al. (eds.), pp. 185-200 (1981).
M. Belles-Isles et al., "In Vitro Activity of Daunomycin-Anti-Alphafoetoprotein Conjugate on Mouse Hepatoma Cells", Br. J. Cancer, 41, pp. 841-842 (1980).
R. Bird et al., "Single Chain Antibody Variable Regions", Trends in Biotech, 9 (4), pp. 132-137 (1991).
A. Blair et al., "Linkage of Cytotoxic Agents to Immunoglobulins", J. Immunol. Methods, 59, pp. 129-143 (1983).
A. Chersi, "Biochemical Aspects of Antibody-Directed Delivery of Toxins and Drugs to Target Cancer Cells", J. Exp. Clin. Cancer. Res, 3, 3, pp. 217-223 (1984).
D. Colcher et al., "In Vivo Tumor Targeting of a Recombinant Single-Chain Antigen-Binding Protein", J. Natl. Cancer Inst., 82 (14), pp. 1191-1197 (1990).
S. T. Crooke, "Goals for Anthracycline Analog Development at Bristol Laboratories", Anthracyclines: Current Status and New Developments, S. T. Crooke et al. (eds.)., pp. 11-13 (Academic Press 1980).
Y. L. Danon et al., "A Monoclonal Antibody to Thy-1 Antigen Conjugates to Adriamycin Inhibits Human Neuroblastoma Cells", Proc. Int. Congr. Chemother., 13th, K. H. Spitzy et al. (eds.), vol. 17, pp. 288/1-288/4 (1983).
T. Deguchi et al., "Potential Therapeutic Effect of Adriamycin-Monoclonal Anti-Prostatic Acid Phosphatase Antibody Conjugate on Human Prostate Tumor", J. Urol., 137, pp. 353-358 (1987).
R. A. DeWeger et al., "Eradication of Murine Lymphoma and Melanoma Cells by Chlorambucil-Antibody Complexes", Immunological Rev., 62, pp. 29-45 (1982).
R. O. Dillman et al., "Preclinical Trials with Combinations and Conjugates of T101 Monoclonal Antibody and Doxorubicin", Cancer Res., 46, pp. 4886-4891 (1986).
M. J. Embelton et al., "Antibody Targeting of Anti-Cancer Agents", Monoclonal Antibodies for Cancer Detection and Therapy, R. W. Baldwin and V. S. Byers (eds.), pp. 317-344 (Academic Press 1985).
C. H. J. Ford et al., "Localization and Toxocity Study of a Vindesine-Anti-CEA Conjugate in Patients with Advanced Cancer", Br. J. Cancer, 47, pp. 35-42 (1988).
J. Gallego et al., "Preparation of Four Daunomycin-Monoclonal Antibody 791T/36 Conjugates with Anti-Tumor Activity", Int. J. Cancer, 33, pp. 737-744 (1984).
T. I. Ghose et al., "Preparation of Antibody-Linked Cytotoxic Agents", Methods Enzymol., 93, pp. 280-333 (Academic Press 1983).
S. Hashida et al., Journal of Applied Biochemistry, 6, pp. 56-63 (1984).
Ho et al., J. Cell Biochem., Suppl. 10A, 37 (Conference Abstract) (1986).
E. Hurwitz et al., "The Covalent Binding of Daunomycin and Adriamycin to Antibodies, with Retention of Both Drug and Antibody Activities", Cancer. Res., 35, pp. 1175-1181 (1975), (Hurwitz I).
E. Hurwitz, "Soluble Macromolecules as Carriers for Daunorubicin", J. Appln. Biochem., 2, pp. 25-35 (1980) (Hurwitz II).
E. Hurwitz, "Specific and Nonspecific Macromolecule-Drug Conjugates for the Improvement of Cancer Chemotherapy", Biopolymers, 22, pp. 557-567 (1983) (Hurwitz III).
E. Hurwitz et al., "A Conjugate of Adriamycin and Monoclonal Antibodies to Thy-1 Antigen Inhibits Human Neuroblastoma Cells in Vitro", Ann N. Y. Acc. Sci., 417, Oncodevelopmental Biology and Medicine, E. Alpert et al. (eds.), pp. 125-136 (Hurwitz IV).
T. Ji, Methods in Enzymology, 91, pp. 580-609, (1983).
D. E. Johnson et al., "Efficacy of an acid-Labile T101-Daunomycin Immunoconjugate in an Athymic Mouse Tumor Model", Proc. Amer. Assoc. Can. Res., 28, p. 389 (1987).
B. Lesur et al., "Convalent Linkages of Anthracyclines to Macromolecular Carriers", Protides Biol. Fluids, 32, pp. 437-440 (1985).
A. Mazzoni et al., "Comparative Distribution of Free Doxorubicin and Poly-L-Aspartic Acid Linked Doxorubicin In MS-2 Sarcomo Bearing Mice", Cancer Drug Delivery, 3 (No. 3), pp. 163-172 (1986).
S. Olsnes et al., "Chimeric Toxins", Pharmac. Ther., 15, pp. 355-381 (1982).
C. Peterson et al., "Transport and Storage of Anthracyclines in Experimentals Systems and Human Leukemia", Anthracycline Antibiotics in Cancer Therapy, from Proc. Int. Symp. on Anthracycline Antibiotics in Cancer Therapy, F. M. Mugia et al. (eds.), pp. 132-146 (Martinus Nijhoff 1982).
V. J. Richardson et al., "Doxorubicin Immunconjugates for Targeting to CEA Expressing Cells in Culture", Tumor Biology, 8 (No. 6), pp. 358-359 (1987).
W. C. Shen et al., "Cis-Aconityl Spacer Between Daunomycin and Macromolecular Carriers: A Modelof PH-Sensitive Linkage Releasing Drug From a Lysosmotropic Conjugate", Biochem. Biophys. Res. Comm., 102 (No. 3), pp. 1048-1054 (1981).
D. L. Simpson et al., "Killing of Cultured Hepatocytes by Conjugates of Asialofetuin and EGF Linked to the A Chains of Ricin or Diphtheria Toxin", Cell, 29, pp. 469-473 (1982).
T. H. Smith et al., "Adriamycin Analogues. 2. Synthesis of 13-Deoxyanthracyclines", J. Med. Chem., 21 (No. 3), pp. 280-283 (1978).
T. Suzuki et al., "The Preparation of Mitomycin C. Adriamycin and Daunomycin Covalently Bound to Antibodies as Improved Cancer Chemotherapeutic Agnets", Chem. Pharm. Bull., 29 (No. 3), pp. 844-848 (1981).
P. E. Thorpe, "Antibody Carriers of Cytotoxic Agetns in Cancer Therapy: A Review", Monoclonal Antibodies '84: Biological and Clinical Applications, A. Pinchera et al. (eds.), pp. 475-506 (1985).
J. M. Varga et al., "Melanotropin-Dau

Affiliated with

Also associated with

Rating

Branched hydrazone linkers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Branched hydrazone linkers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Branched hydrazone linkers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-245655